Tag: Biotech and Pharmaceuticals
-
Fat cat? Weight-loss drugs may be coming for your overweight pet
Startups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.
-
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
-
UnitedHealth blows past estimates, hikes earnings outlook as it reins in costs
The healthcare giant is working to stabilize margins by shrinking membership, exiting unprofitable contracts and pouring $1.5 billion into AI.
-
Johnson & Johnson has a chance to show it’s more than just a rotation winner
The healthcare giant’s second-quarter earnings will shine the spotlight on its exciting new products and pipeline.
-
Biotech’s recovery isn’t a ‘head fake.’ These 3 stocks could lead the next leg up
Biotech remains one of the market’s more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.
-
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk’s obesity injection Wegovy and diabetes counterpart Ozempic.
-
AstraZeneca’s trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
-
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
-
Jim Cramer says this former Covid market darling is finally investable again
CNBC’s Jim Cramer said Moderna’s expanding pipeline in treatments for cancer and other diseases provides a compelling long-term investment thesis.
-
FDA lets Philip Morris market Zyn nicotine pouches as less harmful than cigarettes
The Trump administration has expanded access to nicotine products despite concerns from public health critics about youth use and addiction.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news china cup Donald J. Trump Donald Trump economy European Union fast football France germany Heatwave Investment strategy iran Iran war markets news People per politics return russia said Singapore spain Sport Stock markets technology trump ukraine United Kingdom United States US-Israel attack on Iran 2026 video War in Ukraine World world cup World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
